UnifiedACB

Medication evidence profile

Carbamazepine

Ask about Carbamazepine

Clinical overview

Carbamazepine has public medication-list entries in JARS 2025, Yamada-ABS 2023, BAAS 2019, Swe-ABS 2023, GABS 2018, KABS 2020 open validation supplement, and CALS 2022 Table 4. These are 7 separate source versions, each with its own evidence and definitions.

Source-specific scores

SourceScore
JARS2
Yamada-ABS0
BAAS2
Swe-ABS2
GABS2
KABS1
CALS2

How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.

How to interpret the evidence

7 of 7 public source versions contain an explicit medication-list entry for carbamazepine.

The recorded values differ across the source rows for carbamazepine. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.

Yamada-ABS 2023 explicitly records zero. Those recorded zeros remain different from a missing entry.

Source labels and provenance · 7 observations
  1. Japanese Anticholinergic Risk Scale (JARS) 2025 English translation

    Source label: Carbamazepine. Published value: 2.
    Source version: JARS-2025
    Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=N03AF01
    Observation: JARS_2025_R0012; rating state: published_rating.

  2. Yamada Pharmacological Anticholinergic Burden Scale 2023

    Source label: carbamazepine. Published value: 0.
    Source version: YAMADA-ABS-2023
    Source location: GGI-23-558-s002.docx Table S1 row 7 (Antiepileptics)
    Observation: YAMADA_ABS_2023_R0134; rating state: published_zero.

  3. Brazilian Anticholinergic Activity Scale 2019

    Source label: Carbamazepine. Published value: 2.
    Source version: BAAS-2019
    Source location: RC4 source recovery; recovery_scope=primary_table_complete
    Observation: BAAS_2019_R0048; rating state: published_rating.

  4. Swedish Anticholinergic Burden Scale 2023

    Source label: Carbamazepine. Published value: 2.
    Source version: SWE-ABS-2023
    Source location: RC4 source recovery; recovery_scope=primary_final_nonzero_complete
    Observation: SWE_ABS_2023_R0068; rating state: published_rating.

  5. German Anticholinergic Burden Score 2018

    Source label: Carbamazepine. Published value: 2.
    Source version: GABS-2018
    Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
    Observation: GABS_2018_R0106; rating state: published_rating.

  6. KABS 2019 scale - 2020 open validation supplement

    Source label: Carbamazepine. Published value: 1.
    Source version: KABS-2020-validation-supplement
    Source location: Additional file 1; category Antiepileptics; table row 18
    Observation: KABS2020_SUPP_0063; rating state: published_validation_supplement_rating.

  7. CALS 2022 - primary final Table 4

    Source label: Carbamazepine. Published value: 2.
    Source version: CALS-2022-primary-table4
    Source location: Table 4; literal capture row 19; displayed table row 3; displayed column 5
    Observation: CALS2022_T4_0019; rating state: published_final_table_rating.

What this page does not establish

  • All public source versions represented by this release have an entry for this medication. Coverage of this selected source set does not establish complete evidence for every population or formulation.
  • No route inference unless present in the source label.
  • These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.

References

  1. Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
  2. Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
  3. Nery RT, Reis AMM. Development of a Brazilian anticholinergic activity drug scale. Einstein (Sao Paulo). 2019;17(2):eAO4435. doi:10.31744/einstein_journal/2019AO4435. Open source
  4. Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
  5. Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
  6. Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
  7. Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source

Ask a follow-up

Go to your medication comparison · How UnifiedACB handles disagreement

Ask about this medication

Medication context: Carbamazepine

Ask about this medication
Show Carbamazepine across all available scalesWhy do the scales differ for Carbamazepine?Show the evidence for CarbamazepineCompare Carbamazepine with another medication